ISLMF (InSilico Medicine Cayman TopCo) Beginning Cash Position: $212.13 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Beginning Cash Position?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 Beginning Cash Position is $212.13 Mil as of Dec. 2025. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's Beginning Cash Position for the quarter that ended in Dec. 2025 was $212.13 Mil.

InSilico Medicine Cayman TopCo's quarterly Beginning Cash Position increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($125.94 Mil) and increased from Jun. 2025 ($125.94 Mil) to Dec. 2025 ($212.13 Mil).

InSilico Medicine Cayman TopCo's annual Beginning Cash Position declined from Dec. 2023 ($207.88 Mil) to Dec. 2024 ($177.18 Mil) and declined from Dec. 2024 ($177.18 Mil) to Dec. 2025 ($125.94 Mil).

InSilico Medicine Cayman TopCo Beginning Cash Position Related Terms

InSilico Medicine Cayman TopCo Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Beginning Cash Position Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
161.54 207.88 177.18 125.94

InSilico Medicine Cayman TopCo Quarterly Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial 0.00 177.18 0.00 125.94 212.13
ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $212.13 Mil mean?
InSilico Medicine Cayman TopCo (ISLMF) has a Beginning Cash Position of $212.13 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Beginning Cash Position too high?
InSilico Medicine Cayman TopCo's current Beginning Cash Position is $212.13 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Beginning Cash Position compare to ?
InSilico Medicine Cayman TopCo's Beginning Cash Position of $212.13 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Software company?
A good Beginning Cash Position depends on the Software industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Beginning Cash Position is $212.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Beginning Cash Position of $212.13 Mil. The current Beginning Cash Position is $212.13 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Beginning Cash Position is $212.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price